Search Results

You are looking at 81 - 90 of 1,412 items for :

  • "carcinoma" x
  • Refine by Access: All x
Clear All
Full access

Evolving Roles of Histologic Evaluation and Molecular/Genomic Profiling in the Management of Endometrial Cancer

Rajmohan Murali, Deborah F. Delair, Sarah M. Bean, Nadeem R. Abu-Rustum, and Robert A. Soslow

(FIGO) staging system has its limitations, particularly in the setting of corpus-confined carcinoma. Because the current staging scheme applies uniformly to all cases, irrespective of staging adequacy or tumor type, clinical outcomes are highly variable

Full access

Selection of Patients with Hepatocellular Carcinoma for Sorafenib

Ghassan K. Abou-Alfa

Treatment of Unresectable Hepatocellular Carcinoma . Available at: http://www.fda.gov/CDER/Offices/OODP/whatsnew/sorafenib.htm . Accessed February 9, 2009 . 2 Llovet JM Ricci S Mazzaferro V . Sorafenib in advanced hepatocellular carcinoma . N

Full access

Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology

Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Nilofer Azad, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Ignacio Garrido-Laguna, Jean L. Grem, J. Randolph Hecht, Sarah Hoffe, Joleen Hubbard, Steven Hunt, Hisham Hussan, William Jeck, Kimberly L. Johung, Nora Joseph, Natalie Kirilcuk, Smitha Krishnamurthi, Jennifer Maratt, Wells A. Messersmith, Jeffrey Meyerhardt, Eric D. Miller, Mary F. Mulcahy, Steven Nurkin, Michael J. Overman, Aparna Parikh, Hitendra Patel, Katrina Pedersen, Leonard Saltz, Charles Schneider, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Eden Stotsky-Himelfarb, Anna Tavakkoli, Christopher G. Willett, Grant Williams, Frankie Algieri, Lisa Gurski, and Katie Stehman

project that 1,870 deaths due to anal cancer will occur in the United States in 2023. 1 Although considered to be a rare cancer, the incidence rate of invasive anal carcinoma in the United States increased by approximately 1.9-fold for males and 1.5-fold

Full access

Outcomes of Patients With Advanced Gastrointestinal Cancer in Relationship to Opioid Use: Findings From Eight Clinical Trials

Omar Abdel-Rahman, Hatim Karachiwala, and Jacob C. Easaw

( ClinicalTrials.gov identifiers: NCT01124786, NCT00844649), 2 included patients with advanced gastric cancer (NCT00290966, NCT00678535), 1 included patients with advanced hepatocellular carcinoma (HCC; NCT00699374), and 3 included patients with advanced

Full access

Incorporating New Systemic Therapies in Kidney Cancer Treatment

Eric Jonasch

Over the past decade, a number of new therapies have been approved for the treatment of renal cell carcinoma (RCC; Figure 1 ). Most treatments are driven by clear cell histology, which represents 70% to 75% of all RCCs. Eric Jonasch, MD

Full access

Merkel Cell Carcinoma: A Review of Current Advances

Frank Qian Zhan, Vathani Sharon Packianathan, and Nathalie Charlotte Zeitouni

The authors have no financial interest, arrangement, or affiliation with the manufacturers of any products discussed in the article or their competitors. References 1 Toker C . Trabecular carcinoma of the skin . Arch Dermatol

Full access

New Virus Associated With Merkel Cell Carcinoma Development

Dana E. Rollison, Anna R. Giuliano, and Jürgen C. Becker

Merkel Cell Polyomavirus: The Fifth Human Polyomavirus to be Discovered Merkel cell carcinoma (MCC) is a rare, aggressive neuroendocrine malignancy of the skin with an annual incidence in the United States of 0.34 and 0.17 per 100,000 men and

Full access

NCCN Guidelines® Insights: Merkel Cell Carcinoma, Version 1.2024

Featured Updates to the NCCN Guidelines

Chrysalyne D. Schmults, Rachel Blitzblau, Sumaira Z. Aasi, Murad Alam, Arya Amini, Kristin Bibee, Diana Bolotin, Jeremy Bordeaux, Pei-Ling Chen, Carlo M. Contreras, Dominick DiMaio, Jessica M. Donigan, Jeffrey M. Farma, Karthik Ghosh, Kelly Harms, Alan L. Ho, John Nicholas Lukens, Susan Manber, Lawrence Mark, Theresa Medina, Kishwer S. Nehal, Paul Nghiem, Kelly Olino, Soo Park, Tejesh Patel, Igor Puzanov, Jason Rich, Aleksandar Sekulic, Ashok R. Shaha, Divya Srivastava, Valencia Thomas, Courtney Tomblinson, Puja Venkat, Yaohui Gloria Xu, Siegrid Yu, Mehran Yusuf, Beth McCullough, and Sara Espinosa

10, 2024; Expiration date: January 10, 2025 Learning Objectives: Upon completion of this activity, participants will be able to: • Integrate into professional practice the updates to the NCCN Guidelines for Merkel Cell Carcinoma

Full access

Optimal Surveillance Strategies After Surgery for Renal Cell Carcinoma

Mark D. Tyson and Sam S. Chang

The incidence of renal cell carcinoma (RCC) has been steadily increasing for decades. 1 The mainstay of treatment for clinically localized disease is radical nephrectomy and, when technically feasible, partial nephrectomy. Yet, up to 20% to 30

Full access

New Treatments for Renal Cell Carcinoma: Targeted Therapies

Philip J. Saylor and M. Dror Michaelson

Petrylak D Thompson S . Cytotoxic chemotherapy for advanced renal cell carcinoma . Urol Clin North Am 1993 ; 20 : 303 – 321 . 3 Atkins MB Regan M McDermott D . Update on the role of interleukin 2 and other cytokines in the treatment of